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ABSTRACT
Metastatic Melanoma (MM) is a deadly form of skin cancer and many 
photodynamic therapy (PDT) studies have noted limitations in relation to effective 
photosensitizer (PS) drug uptake in tumors. The focus of this study was to develop 
a PS multicomponent nanoparticle drug conjugate carrier system which specifically 
targets MM cells via biomarkers to actively enhance PS delivery and so improve MM 
PDT. An antibody-metallated phthalocyanine-polyethylene glycol-gold nanoparticle 
drug conjugate, was successfully synthesized and characterized. PS active drug 
targeting PDT experiments at 673 nm were conducted within in vitro cultured 
MM. Results noted that this drug conjugate enhanced the PDT treatment of MM, 
through improved subcellular localization of the PS, as well as noted significantly 
improved cytotoxic and late apoptotic cellular death in cells. The results from this 
study demonstrate that through the bio-active antibody PS drug targeting of MM, the 
efficacy of PDT treatment for this cancer can be enhanced.
INTRODUCTION
Melanoma represents about 10% of all skin 
malignancies, however due to its ability to metastasize 
and spread, it accounts for more than 80% of all skin 
cancer related deaths, with approximately 100000 
fatalities annually [1, 2]. There are currently various 
cancer treatments available for melanoma such 
as chemotherapy, surgery, biological therapy and 
radiotherapy or immunotherapy, however, these treatments 
are sometimes invasive and induce harsh unwanted side 
effects. Therefore, investigation into unconventional forms 
of treatment for melanoma such as PDT administered 
alone or in combination with other therapies need to be 
conducted to reduce the side effects and be non-invasive 
[3]. In relation to immunotherapy the standard of care 
of MM patients, include immunomodulating modalities 
such as anti-PD-1 drugs (nivolumab, pembrolizumab) and 
anti-CTLA-4 antibody ipilimumab which have provided 
“proof of concept” for further research in the field of 
immunooncology, however to date this treatment option 
still remains unavailable [4].
PDT involves the administration of a light sensitive 
non-toxic drug known as a PS which passively localizes 
in tumor cells [3, 5] When this PS is irradiated with visible 
red light (620 - 690 nm), it becomes excited and so forms 
cytotoxic reactive oxygen species (ROS) [3, 5]. ROS 
accomplishes photo-cytotoxicity by promoting cellular 
oxidative stress, which induces cell death and so causes 
tumor destruction [5].
PDT is a feasible treatment modality for cancer, 
however, in relation to MM various studies have noted 
some PS drawbacks [2, 3]. Since conventional PS drugs 
can only passively diffuse into tumor cells, it has been 
noted that sometimes they are absorbed by healthy tissues, 
causing undesirable side effects and tend to be absorbed 
in lowered concentrations than originally administered 
[6]. Additionally, PSs are recognized as foreign matter by 
biological barriers and so in vivo tend to be destroyed by 
immune system barriers, resulting in a poor drug uptake 
[7]. Moreover, solid melanoma tumors are seemly more 
resistant to PDT, due to poor absorption of PS drugs and 
limitations of laser light being able to reach these cells 
[3]. Literature has noted positive PDT treatments of MM 
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with zinc sulpho phthalocyanine (ZnPcSmix) PSs, due to 
their longer light wavelength absorption peaks above 650 
nm, being able to penetrate deep seated tumors, rich in 
melanin, however noted that ZnPcS tends to aggregate, 
due to their poor water solubility and sulpho purity, so this 
limited their overall PDT effectivity [8].
Numerous studies have reported that gold 
nanoparticles (AuNPs) can be utilized as drug carriers 
in PDT applications to improve PS passive uptake in 
tumor cells, due to their abilities to avoid biological 
barriers, ease of functionalization, as well as abilities to 
promote photothermal cell death induction due to their 
metallated content.[9–12] Additionally, studies have 
noted that Melanoma Inhibitory Activity (MIA) is an 
antigen, which is specially overexpressed on melanoma 
cells only, thus making it a highly specific and sensitive 
biomarker for MM drug uptake targeting [13]. Thus, 
the conjugation of a MM tumor-targeting antibody 
(Ab) such as Anti-MIA, onto a sulpho pure ZnPcS PS 
carrying AuNPs surface would seem highly desirable, in 
order to promote drug solubility, as well as active MM 
tumor targeting uptake in order to enhance PDT seems 
promising [14–16]. Furthermore, studies have reported 
that Zinc phthalocyanine tetra-sulphonic acid (ZnPcS4) is 
more soluble than ZnPcSmix, due to its tetra sulphonated 
groups [8]. Additionally, studies have determined the 
threshold for acute toxicosis of parenterally administered 
ZnPcS4, in mice and evaluated the compound’s safety in 
a phase I clinical trial of ZnPcS4 based PDT in pet dogs 
with naturally occurring tumors. These animal studies 
confirmed the good tolerability and systemic safety of 
ZnPcS4, as no changes in immunological, behavioral and 
organic parameters could be detected upon treatment 
with the non-photoactivated ZnPcS4 and so show the 
extraordinary photoactive potential of the ZnPcS4 as a 
photosensitizer for PDT [17–20].
Thus, this study ZnPcS4 PS drug was conjugated 
onto the surface of amine functionalized AuNPs, which 
had Anti-MIA antibodies bound to its surface in order 
to actively improve PS drug delivery and increase its 
uptake and absorption within MM target tumor cells. The 
outcome of this study clearly enhanced PDT treatment for 
this type of skin cancer (Figure 1) [17, 18].
RESULTS
Molecular characterization of the final PS drug 
conjugate
UV-Visible spectroscopy
The absorption spectra of the final PS drug 
conjugate were read using the spectrum/purity scan 
mode within the 400-800 nm spectral region (Figure 2). 
500 µM of ZnPcS4 noted two major Q bands of emission 
(634 and 674 nm) within the far-red spectral range and 
AuNP-PEG5000-CSH-NH2 noted a peak absorption band 
of 520 nm, which equates to 2.85 × 1015 particles/ml [21]. 
When both of these absorption spectra were compared to 
the final PS drug conjugate, both absorption peaks still 
remained prominent, however lowered in absorption, 
confirming that ZnPcS4 had been successfully bound to 
AuNP-PEG5000-SH-NH2, and the PS ROS integrity, 
as well as AuNP photothermal properties had remained 
intact. When comparing the major absorption peak fold 
falls of the PS drug conjugate to ZnPcS4 and AuNP-
PEG5000-SH-NH2 controls, it was determined that 0.89 
× 1015 AuNP-PEG5000-SH-NH2 particles/ml had been 
successfully bound to 227 µM of ZnPcS4 PS drug. Since, 
the major absorption peaks of the final PS drug conjugate 
at 520 and 673 nm in relation to ZNPcS4 and AuNP control 
peaks did not broaden much, this suggests the final PS 
drug conjugate had good size distribution with minimal 
aggregation [22]. However, since the absorption peaks of 
the final PS drug conjugate did slightly broaden; this is 
indicative of definitive bonding between all the chemical 
components, as there is an obvious increase in molecular 
size [23]. Moreover, the slight shift in the resonance peak 
position of AuNP at 520 nm, within the final molecular 
conjugate was also indicative that ZnPcS4 and Anti-MIA 
Ab had successfully bound to its surface [23]. Finally, 
over 8 weeks of the experimental assays the absorption 
spectra Q bands of 520, 634 and 674 nm stayed consistent, 
suggesting the final PS drug conjugate remained 
photostable and retained its photothermal properties after 
molecular synthesis and overtime (Figure 3).
With reference to Figure 4, the protein direct UV 
280 nm spectral region of the final PS drug conjugate 
noted a 5.8 absorbance fold fall when compared to control 
200 µg/ml Anti-MIA Ab within the same spectral range. 
This finding suggests that only 34 µg/ml of Anti-MIA Ab 
was successfully bound to the final molecular PS drug 
conjugate. According to literature, amine (NH2) functional 
groups produce a high absorption peak at a wavelength 
spectrum of 195 nm, whereas the condensation of an 
amine with a carboxylic acid to produce an amide peptide 
bond (CO-NH) tend to produce a high absorption peak at a 
wavelength spectra of 220 nm [24]. The AuNP-PEG5000-
SH-NH2 control noted a high NH2 group absorption peak 
at a wavelength spectrum of 195 nm, which is expected 
since it was NH2 functionalized. Additionally, the Anti-
MIA Ab control also noted a high NH2 group absorption 
peak at 195 nm, which is predictable considering its n’ 
terminal has NH2 functional groups. Whereas, the final PS 
drug conjugate noted lowered NH2 group absorption peak 
at 195 nm, when compared to that of the AuNP control, 
suggesting that NH2 group on the AuNP had condensed 
with the activated carboxylic group on the activated c’ 
terminus of the Abs to produce a CO-NH bond. The final 
CO-NH bond was additionally confirmed, by observing 
the high 220 nm absorption peak within the final PS 
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drug conjugates spectra. Moreover, since the final PS 
drug conjugate still noted the presence of NH2 functional 
groups at the 195 nm absorption peak, this suggested 
that the n’ terminus active targeting sites of the Anti-
MIA Ab within the final multicomponent active nano PS 
molecular drug conjugate remained unaffected, correctly 
orientated (i. e. bound to the AuNP-PEG5000-SH-NH2 at 
c’ terminus) and so were considered functional for active 
Figure 1: Theorized active targeted final PS molecular drug conjugate ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-MIA 
Ab structure and bond formation.
Figure 2: UV-Visible absorption spectra of the final molecular PS drug conjugate (ZnPcS4 -AuNP-PEG5000-SH-NH2 
- Anti-MIA Ab) and various controls within the 400 to 800 nm spectral region.
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PS drug delivery. Lastly, the final PS drug conjugate 
had a higher absorption spectra within the 250 to 280 
nm range than when compared to AuNP and ZnPcS4 
controls, suggesting possible ligand absorption between 
the sulphonated ZnPcS4 PS and AuNP-PEG5000-SH-NH2, 
had occurred in order to create di-sulphide bond [25].
FT-IR spectroscopy
FT-IR spectroscopy has various applications in 
structural identification, and can be used for qualitative 
analysis of molecular ligand and absorption bond 
formations, as well as peptide bond identification within 
the final PS drug conjugate (Figure 5) [26–29]. FT-IR 
Figure 3: UV-Visible absorption and fluorescent photostability spectra of the final molecular PS drug conjugate 
(ZnPcS4 -AuNP-PEG5000-SH-NH2 - Anti-MIA Ab) recorded within the 400 to 800 nm spectral region over an 8-week 
period.
Figure 4: UV-Visible protein direct absorption spectra of the PS drug conjugate and various controls within the 200 
to 310 nm spectral region.
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characterization results revealed the presence of Au-S 
ligand exchange bonding, since the spectra of control 
conjugate ZnPcS4 - AuNP-PEG5000-SH-NH2, noted a 
C-S (1050-1200 cm–1) stretch shift, suggesting AuNP-
PEG5000-SH-NH2 lost their C-S groups to bond with 
ZnPcS4 [26, 27]. Moreover, the presence of Au-S ligand 
exchange bonding was confirmed since the FT-IR spectra 
of ZnPcS4 - AuNP-PEG5000-SH-NH2 noted a loss of a 
C-S (1200 cm–1) sharp band when compared to ZnPcS4 
alone, suggesting ZnPcS4 lost its C-S groups to bond with 
AuNP-PEG5000-SH-NH2 [28]. Finally, the FT-IR spectra 
of ZnPcS4 - AuNP-PEG5000-SH-NH2 noted a sharp S-S 
(500-540 cm–1) bend suggesting that ligand absorption 
between the sulphonated ZnPcS4 PS and AuNP-PEG5000-
SH-NH2 occurred to form a weak di-sulphide bond [29].
Furthermore, the final molecular conjugate (ZnPcS4 
- AuNP-PEG5000-SH-NH2 - Anti-MIA Ab) was also 
subjected to FT-IR analysis for confirmatory amide bond 
analysis, by noting and identifying the formation of amide 
bonds when compared to the FT-IR spectra of AuNP-
PEG5000-SH-NH2 alone (Figure 6). With referral to Figure 
6, FT-IR characterization revealed that final molecular 
conjugate noted a C=O (1680-1630 cm–1) stretch and sharp 
N=H bend (1640-1650 cm–1), when compared to the AuNP-
PEG5000-SH-NH2 alone, suggesting that strong primary and 
secondary amide peptide bonds (CO-NH) formed between 
the amine (NH2) functionalized group on the AuNPs and the 
activated c’ terminus of the Anti-MIA Ab [29].
Dynamic light scattering and zeta potential
DLS and ZP results are shown in Table 1 and Figure 
7. The DLS hydrodynamic radius distribution of the final 
PS drug conjugate noted a single narrow width peak, 
indicating it remained spherical with no aggregation and 
was homogenously pure. The final PS drug conjugate 
reported a mean Z-average diameter of 45.20 ± 6.458 nm, 
suggesting it was indeed small enough to be considered 
as an active nanodrug carrying system [30]. The final PS 
conjugate reported a PDI purity value of 0.306, signifying 
it was monodisperse and mostly consisted of single sized 
particles. The ZP value of the final PS drug conjugate 
was found to be 28.6 ± 3.73 mV, proposing that it was 
moderately stable with a slightly positively charge, hinting 
at the fact that it should remain stable within an in vivo 
environment, as well as be passively be taken up and 
retained within tumorous cells more selectively [30, 31].
Subcellular localization
Immunofluorescent studies noted a far more 
predominant localization of ZnPcS4 PS (red) in the 
cytoplasm (green) and nuclei (blue) of MM cells, which 
received the final PS drug conjugate, than when compared 
control PS drug administration alone (Figure 8). These 
findings suggest that the targeting affinity of the PS 
drug conjugate in relation to Anti-MIA Ab biomarker 
specify for MM cells was functional, and so improved the 
subcellular localization and concentration uptake within 
these cells.
ZnPcS4 PS PDT dose response assay
In order to establish the IC50 of the ZnPcS4 PS, 
various concentrations of ZnPcS4 PS and/or PDT laser 
irradiation (at a wavelength of 673 nm using a fluency 
of 10 J/cm2) were applied to MM cells and results were 
reported in the form of Trypan Blue Exclusion cell 
Figure 5: FT-IR spectra analysis for confirmatory ligand exchange (Au-S) and absorption (S-S) bond confirmation 
between AuNP-PEG5000-SH-NH2 and ZnPcS4 within the final PS drug conjugate.
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viability tests (Figure 9) and Lactate Dehydrogenase 
(LDH) cytotoxicity and membrane integrity assay results 
(Figure 10).
The Trypan Blue Exclusion cell viability test 
(Figure 9) noted control MM cells, which received various 
concentrations of ZnPcS4, with no laser irradiation applied 
to them, that there was an insignificant dose dependent 
decrease in cell viability. This suggested that the ZnPcS4 in 
its inactivated form, when administered alone lacks dark 
toxicity. Additionally, control MM cells which received 
laser irradiation alone, also noted no cellular damage. 
Experimental groups of MM cells which received 0.25 
and 0.5 µM of ZnPcS4 and laser irradiation, showed no 
significant decreases in cell viability. However, cells 
which received 1, 2.5, 5 and 10 µM of ZnPcS4 with laser 
irradiation showed dose dependent significant decreases 
in cell viability, when compared to the cells only control. 
The LDH cytotoxicity and membrane integrity assay 
(Figure 10) reported similar significant results within 
experimental groups which received 1, 2.5, 5 and 10 µM 
of ZnPcS4 with laser irradiation, while all control groups 
noted insignificant findings.
These results indicate that ZnPcS4 is an excellent 
PS for the use of PDT on MM, since it is capable of 
Figure 6: FT-IR spectra analysis for confirmatory amide (CO-NH) bond confirmation between AuNP-PEG5000-SH-
NH2 and the activated carboxylic group on the c’ terminus of the Anti-MIA Ab within the final PS drug conjugate.
Figure 7: DLS hydrodynamic radius distribution graph of final molecular drug conjugate consisting of ZnPcS4 - 
AuNP-PEG5000-SH-NH2 - Anti-MIA Ab.
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substantial cell death induction. However, in order to 
establish if the PS when administered in a drug carrying 
conjugate, was capable of targeted and improved PDT, 
the IC50 of 2.5 µM ZnPcS4 PS with laser irradiation 
applied was chosen, as it reported a significant 
decrease of 38%** in cell viability and 48%** cellular 
cytotoxicity. Thus, in relation to the below final 
conjugate studies: the concentration of the final PS drug 
Table 1: DLS and ZP results for characterization of final molecular NP PS drug delivery system
Sample Mean Z-Average Diameter 
Measured by DLS (nm)
Polydisersity Index (PDI) Zeta Potential (mV)
AuNP 11.06 ± 1.02 0.247 (Monodisperse)
ZnPcS4 15.44 ± 2.23 0.406 (Monodisperse)
Expected average ZnPcS4 - 
AuNP 41.94 ± 1.63
Result average ZnPcS4 - 
AuNP 42.94 ± 3.625 0.289 (Monodisperse)
Anti-MIA Ab 3.21 ± 1.83 0.352 (Monodisperse)
Expected average ZnPcS4 - 
AuNP - Anti-MIA Ab 49.36 ± 2.73
Result average ZnPcS4 - 
AuNP - Anti-MIA Ab (final 
molecular drug conjugate)
45.20 ± 6.458 0.306 (Monodisperse) 28.6 ± 3.73 (Moderately stable)
Figure 8: Subcellular localization results of ZnPcS4 PS alone verses PS drug conjugate within in vitro cultured MM 
cells. (Blue = nuclei, green = membrane proteins and red = localization of ZnPcS4 PS drug).
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conjugate that was administered to cells consisted of 
2.5 µM ZnPcS4 PS, bound to 0.425 µg/ml Anti-MIA Ab 
with 1.11 × 1013 AuNP-PEG5000-SH-NH2 particles/ml 
in 0.001 M PBS.
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-
MIA ab final PS drug conjugate PDT response 
assays
Morphological assessment
Changes in cellular morphology of various control 
group and PDT experimental groups, were assessed 24 
hours post irradiation by light microscopy by comparing 
these images to the MM cells only control (Figure 11). 
No significant morphological damage was noted in 
the cells control group which received laser treatment 
only, suggesting laser treatment alone doesn’t induce 
phototoxicity. Control cell groups which received 2.5 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 or 2.5 µM final 
PS drug conjugate only, no significant change in cellular 
morphology was observed, signifying that the final 
molecular drug conjugate exhibited no dark toxicity.
Within the PDT treated control groups, which 
received with 2.5 µM ZnPcS4 – AuNP-PEG5000-SH-
NH2, changes in morphological structure, such as loss 
of cellular shape, detachment and free-floating cells was 
observed. These results are supported by studies by Conde 
Figure 9: Trypan blue exclusion cell viability results of control and experimental groups of ZnPcS4 at various 
concentrations with and without laser irradiation at 673 nm at 10 J/cm2
Figure 10: LDH cellular cytotoxicity assay results of control and experimental groups of ZnPcS4 at various 
concentrations with and without laser irradiation at 673 nm at 10 J/cm2.
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et al. (2012) whom noted that within PDT applications 
AuNPs have laser light induced photothermal properties, 
which assist in tumor destruction [12]. However, the 
most significant cellular damage was noted within the 
PDT treated experimental group, which received 2.5 
µM of the final PS drug conjugate, as cells appeared to 
be completely detached, rounded up and cellular debris 
was seen. These findings suggest that the final PS drug 
conjugate Anti-MIA Ab actively enhanced cellular 
uptake of the ZnPcS4 and so enhanced the PDT treatment 
outcome. These findings correlate with studies by Hong 
et al. (2016), which highlight that NP PS drug uptake and 
absorption can be improved, when NPs are functionalized 
with targeting biomolecules, which allow for active and 
specific targeted delivery in tumor cells and so enhance PS 
cellular localization and overall PDT outcome [32].
Trypan blue exclusion test
In order to determine the effect, the final PS drug 
conjugate had during PDT response assays, various control 
and experimental groups were subjected to Trypan blue 
exclusion staining (Figure 12). The MM cells only control 
group noted 98% viable cells and so this was used as 
reference-base line to statistically compare other results 
against. Control groups which received laser irradiation 
only, no substantial decrease in viability was found, 
suggesting laser irradiation alone, had no effect on cellular 
viability. Similarly, control cells which received 2.5 µM 
Figure 11: Light microscopy morphological images of MM cells at 400× magnification of control and experimental 
groups that were subjected to laser irradiation at a wavelength of 673 nm and a fluence of 10 J/cm2 during final PS 
drug conjugate PDT response assays.
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ZnPcS4 only, noted no significant decrease in cell viability, 
suggesting that this PS drug when administered at this 
concentration, lacks dark toxicity in cells. Additionally, 
there was no significant viability decrease observed in 
cell control groups which received control 2.5 µM ZnPcS4 
– AuNP-PEG5000-SH-NH2 or 2.5 µM final PS drug 
conjugate administration alone. These findings indicate 
that even when the ZnPcS4 was bound to either AuNP-
PEG5000-SH-NH2, as well as Anti-MIA Ab, it remained 
stable (in its inactive form) and so lacked dark toxicity.
The PDT treated groups, which consisted of cells 
with the addition of either 2.5 µM ZnPcS4, 2.5 µM ZnPcS4 
– AuNP-PEG5000-SH-NH2 or 2.5 µM final PS drug 
conjugate showed varying significant decreases in cell 
viability. The PDT treated control group which received 2.5 
µM ZnPcS4 with laser irradiation noted a 46%* decrease in 
cell viability, whereas the PDT treated control group which 
received 2.5 µM ZnPcS4 – AuNP-PEG5000-SH-NH2 with 
laser irradiation noted an even more significant decrease of 
69%** in cell viability. These findings are indicative that 
the bound AuNPs to the PS promoted PDT photothermal 
induced cellular damage, than when compared to PS drug 
administration alone [32]. However, the most significant 
decrease of 84%*** in cellular viability, was noted in PDT 
treated experimental group which received 2.5 µM final 
PS drug conjugate. These findings suggest that the Anti-
MIA Ab, which was conjugated to the final PS drug carrier, 
actively enhanced PS drug uptake in cells and so improved 
PDT treatment outcomes immensely.
LDH cellular cytotoxicity and membrane integrity assay
In order to determine the cytotoxic effect, the final 
PS drug conjugate had during PDT response assays, 
various control and experimental groups were subjected 
to LDH membrane damage integrity analysis (Figure 13). 
The MM cells only control group noted negligible 
cytotoxicity and so this was used as reference-base line 
to statistically compare other results against. Control 
groups which received laser irradiation or 2.5 µM ZnPcS4 
only, no substantial increase in cellular cytotoxicity was 
found, suggesting that laser treatment alone or PS addition 
pre-PDT has significant impact on cellular cytotoxicity. 
Additionally, there was no significant cytotoxicity increase 
observed in cell control groups, which received control 2.5 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2 or 2.5 µM final 
PS drug conjugate administration alone. These findings 
indicate that when the ZnPcS4 was bound to either AuNP-
PEG5000-SH-NH2, and /or Anti-MIA Ab, pre-PDT it 
remained stable and had no cytotoxic effects on cells.
All PDT treated groups reported highly significant 
cellular cytotoxicity values which varied over the different 
groups. Within PDT treated control groups which received 
2.5 µM ZnPcS4 PS drug only, a significant increase 
of 45%*** cellular cytotoxicity was noted. However, 
within PDT treated control groups which received 2.5 
µM ZnPcS4 – AuNP-PEG5000-SH-NH2, a significantly 
higher increase of 59%*** was found. These findings 
are supportive of previous results, whereby it has been 
stated that the binding of AuNPs to PSs stimulate PDT 
induced photothermal activities, which in turn are 
cytotoxic to cells [32, 33]. However, the most significant 
cellular cytotoxicity of 73%*** was noted in PDT treated 
experimental groups, which received 2.5 µM final PS 
drug conjugate administration. These findings suggest 
that the conjugation of Anti-MIA Ab to ZnPcS4 – AuNP-
PEG5000-SH-NH2, actively enhanced PS uptake in MM 
cells and so improved cellular cytotoxicity post-PDT 
treatment outcomes significantly.
Flow cytometry Annexin V-FITC/PI cell death pathway 
detection assay
This assay was performed in order determine if 
the final PS drug conjugate was capable of enhanced 
PDT induced cell death, due to its functionalized active 
Figure 12: Trypan blue exclusion MM cell viability results of control and experimental groups that were subjected to 
final PS drug conjugate PDT response assays.
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Ab targeting abilities and AuNP photothermal promoting 
nanocarrier, when compared to ZnPcS4 PS drug or AuNP-
PEG5000-SH-NH2 administration alone within various 
control and experimental groups. Flow cytometry scatter 
grams acquired for the various control and experimental 
groups were thoroughly analysed, and results have 
been graphically presented in Figure 14. The control of 
cells only was used to statistically compare results of 
viable cells, whereas the necrosis and apoptosis (early 
and late) controls were used to statistically compare 
cells undergoing these various modes of cell death. All 
PDT control and experimental treated groups showed 
significant modes of cell death when compared to the 
viable cells only control group, however these significant 
increases in percentage values varied over the different 
groups in relation to the mode of cell death each group 
had undergone.
Within PDT treated control groups which received 
2.5 µM ZnPcS4 PS drug, only 52%** of the cells were 
found viable and the remainder were reported in a 32%** 
early apoptotic and 16%* in a late apoptotic phase of cell 
death. These results suggest that the administration of 
ZnPcS4 PS drug only with PDT activation has the ability to 
induce 48% apoptotic cell death in MM cells. These results 
coincide with studies conducted by Robertson et al. (2010) 
which also reported that PDT laser activated ZnPcSmix 
administered to melanoma skin cancer cells significantly 
decreased proportion of viable cells, as well as significantly 
increased the number of cells undergoing early 
apoptosis [34]. Nevertheless, studies by Noguchi et al.  
(2015) have stated that cells undergoing early apoptosis 
modes of cell death, often remain in an autophagy phase 
and so have the ability to recover [35]. Thus, idealistically, 
this early mode of apoptotic cell death is not favourable in 
PDT cancer treatments, as cells can regenerate themselves 
and so there is a possibility of cancer re-occurrence.
Whereas, within PDT treated control groups which 
received 2.5 µM ZnPcS4 – AuNP-PEG5000-SH-NH2, 
a more significant increase of 27%*** in late apoptosis 
was noted, with a 40%*** in early apoptosis, 5%** 
undergoing necrosis and only 28%** of cells being found 
viable. The improved result of MM cells in late apoptosis 
when compared to the cells only or PDT treated groups 
which received 2.5 µM ZnPcS4 PS was again attributed 
to presence of the AuNPs. Studies by El Hussein et al. 
(2015), support these findings stating that within PDT 
assays performed on cancer cells, that spherical-oval 
shaped AuNPs demonstrated the ability to activate a PDT 
photo thermal apoptotic cell death effects, through notable 
decreases in cell viability and proliferation, as well as an 
increase in cytotoxicity [36].
However, the most significant modes of cell death 
was found within PDT treated experimental groups, which 
received 2.5 µM final PS drug conjugate administration, 
whereby only 13%*** of the cells were found viable, 
12%*** were undergoing early apoptosis and a staggering 
64%*** were found in a late apoptotic cell death phase, 
with a notable 11% increase in necrotic cells. This highly 
significant result of MM cells undergoing 65% late 
apoptosis, when compared to the control groups of cells 
only and PDT treated control groups which received 2.5 
µM ZnPcS4 PS drug only or 2.5 µM ZnPcS4 – AuNP-
PEG5000-SH-NH2, can be accredited to the fact that 
ZnPcS4 PS drug was conjugated to Anti-MIA Ab and so 
actively enhanced PS drug uptake. According to studies 
by Bazak et al. (2015) significant progress has been made 
in terms of specific receptor based PS drug molecular 
targeting of cancer cells though the conjugation of PSs 
Figure 13: LDH cellular cytotoxicity assay results of control and experimental groups that were subjected to final PS 
drug conjugate PDT response assays.
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to nano-carriers, which are further functionalized with 
Ab biomarkers, to improve PS drug active absorption in 
targeted cells only, leaving healthy surrounding tissues 
unaffected and overall improving the late apoptotic 
cell death mode efficacy induction of PDT tumour 
treatment [37]. Additionally, studies by Pleshkan et al. 
(2011) indicated that the use of Anti-MIA Ab biomarker 
conjugated drugs are a promising anti-tumour vehicle 
for the successful targeted drug delivery and improved 
treatment of MM [38].
DISCUSSION
The various molecular characterization assays 
confirmed that ZnPcS4 PS drug was successfully 
conjugated onto the surface of AuNPs via ligand 
absorption and exchange methods. Additionally, these 
same assays noted effective c’ terminus amide bonding of 
Anti-MIA Abs onto the surface of functionalized amine 
surface AuNPs, leaving the n’ terminus of the Anti-
Ab correctly orientated outwards and unobstructed for 
active tumor biomarker recognition. DLS and ZP results 
in relation to the final PS drug conjugate noted that the 
nanoparticle drug system was homogenously pure, 
monodispersed and moderately stable and so could be 
considered as an effective PDT PS drug carrier. Moreover, 
the subcellular localization results reported that the final 
PS drug conjugate was more efficient at improved ZnPcS4 
concentrated cellular absorption within the cytoplasm and 
nuclei of cells, due to its Anti-MIA Ab biomarker targeting 
affinity for MM cells.
The findings from this study suggest that the 
conjugation of Anti-MIA Ab to ZnPcS4 – AuNP-PEG5000-
SH-NH2, within the final PS drug conjugate actively and 
specifically enhanced ZnPcS4 PS drug uptake in MM cells, 
in comparison to ZnPcS4 PS drug administration alone. 
Thus, the final PS drug conjugate noted significantly 
enhanced PDT induced cytotoxic cell death in MM cancer 
cells, in comparison to control groups. These results were 
also attributed to the PDT induced photothermal cellular 
destruction abilities of the AuNPs. Additionally, the 
majority of MM cells which received the final PS drug 
conjugate and PDT, were found to be undergoing late 
apoptotic mode of cell death in comparison to ZnPcS4 
PS drug administration alone. Therefore, the results 
from this study suggest that the ZnPcS4 PS drug delivery 
within in vitro cultured MM cells can be improved using 
active nanoparticle biomarker targeting and so the overall 
outcomes of PDT treatment can be enhanced. Additionally, 
in relation to the findings from this study, the efficacy of 
MM treatment could possibly be further upgraded in some 
groups of clinical patients undergoing immunotherapy by 
utilizing the same Anti-MIA Ab as a molecular target and 
observing its treatment outcomes [4].
METHODS
Chemical synthesis of final conjugate ZnPcS4 
– AuNP-PEG5000-SH-NH2 – Anti-MIA Ab: 
Conjugation of Anti-MIA Ab to ZnPcS4 - AuNP-
PEG5000-SH-NH2
Working concentration of 0.0005 M ZnPcS4 (Santa 
Cruz®: sc-264509A) (%w/v) in 0.001 M Phosphate Buffer 
Saline (PBS) was prepared and diluted as needed. 1 ml of 
AuNP-PEG5000-SH-NH2 (Sigma-Aldrich: 765309) which 
contained 2.85 × 1015 AuNPs per ml was added to 1 ml 
of 0.0005 M stock ZnPcS4. It was vortexed at 1 500 rpm 
at room temperature overnight to promote spontaneous 
ligand exchange (between Au and PS tetra sulphides) 
and adsorption (disulphide bond between PEG and PS) 
(Figure 1). It was purified by micro-centrifugation at 15 
200 rpm for 1 hour. The supernatant was discarded and 
the pellet which contained the conjugated ZnPcS4 and 
AuNP-PEG5000-SH-NH2 was re-suspended in 1 ml PBS 
[26, 39].
200 µg/ml of Anti-MIA Ab (Abcam: 166932) was 
activated using covalent mode carbodiimide crosslinker 
Figure 14: Evaluation of different stages of cell death using flow cytometry Annexin V-FITC/PI staining method on 
control and experimental groups that were subjected to final PS drug conjugate PDT response assays.
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two-step coupling EDC and NHS chemistry [23, 25, 40, 
41]. The activated c’ terminus succinimidyl ester on the 
Anti-MIA Ab reacted was then able to react with the amine 
group (NH2) on the AuNPs, already bound in the ZnPcS4 
– AuNP-PEG5000-SH-NH2 conjugate, and so when 
mixed together, formed a stable amide bond [39]. This 
method ensured the correct orientation of the bio-targeting 
antibody, i. e.: the c’ terminus was bound to the amine 
functionalized AuNPs, while the n’ terminus antigenic 
sites remained free and functional for active targeting 
(Figure 1). The final PS drug conjugate (ZnPcS4 – AuNP-
PEG5000-SH-NH2 – Anti-MIA Ab) was then subjected to 
various molecular characterization assays including; UV-
Visible and FT-IR Spectroscopy, DLS and ZP, as well as 
immunofluorescent staining subcellular localization and 
uptake confirmation assays.
Molecular characterization of final conjugate 
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-
MIA Ab
UV-Visible spectroscopy
The UV-Visible absorption and fluorescent spectra 
of the final conjugate ZnPcS4 – AuNP-PEG5000-SH-NH2 
– Anti-MIA Ab and various controls (ZnPcS4, AuNP-
PEG5000-SH-NH2, Anti-MIA Ab, ZnPcS4 - AuNP-
PEG5000-SH-NH2) were recorded using a Jenway Genova 
Nano Plus Life Science Spectrophotometer, to observe 
binding of the Anti-MIA Ab and ZnPcS4 PS to the surface 
of the AuNP-PEG5000-SH-NH2. The absorption and 
fluorescent spectra were read using the spectrum/purity 
scan mode within the 198 - 800 nm spectral region, as 
well as read using the 220 nm protein direct UV option. 
The Anti-MIA Ab protein and ZnPcS4 PS concentration, 
as well as number of bound AuNP to the final conjugate 
was confirmed, after data interpretation [22]. To determine 
the photostability of the final conjugate the ZnPcS4 – 
AuNP-PEG5000-SH-NH2 – Anti-MIA Ab Soret and Q 
bands values were measured prior to laser light irradiation 
experiments over an 8 week period.
FT-IR Spectroscopy
FT-IR analysis was performed using the Nicolet iS50 
FT-IR Spectrometer (Thermo Scientific) to confirm ligand 
exchange / absorption (by noting and identifying the formation 
of strong Au-S and weak di-sulphide bonds), as well as 
confirm amide bond formation (by noting and identifying the 
formation of amide bonds). The infrared spectra results were 
recorded using far infra-red solution software at frequencies 
ranging from 400 - 4000 cm–1 with 25 scans.
DLS and ZP
DLS and ZP measurements were performed using 
the Malvern Zetasizer Nano ZS (Malvern Instruments, 
Malvern UK), which has a 4 mW He-Ne laser of 633 nm 
wavelength. Samples were heterogeneous or homogenous 
10 - 50 µg/ml diluted suspensions in water and were 
analyzed at 25°C, using a 13° and 173° angel.
Subcellular localization
Culture plates were seeded at 2.5 × 105 cells/
ml with A375 MM cells, which had sterile coverslips 
inserted into them and incubated at 37 °C for 4 hours, to 
allow for cellular attachment. After 4 hours of incubation, 
the growth media was discarded and replaced with 
fresh growth media which contained a pre-determined 
dose response of 2.5 µM PS alone or the final PS drug 
conjugate to make up a final volume of 3 ml.
The plates were incubated at 37 °C for an additional 
20 hours in the dark. After incubation, the primary Ab 
[200 µg/ml ICAM-1 Mouse Monoclonal IgG1 Ab diluted 
in 0.01 M PBS in 1% (w/v) BSA and 0.01% (w/v) sodium 
azide buffer solution, in a ratio 1:200] was added followed 
by the secondary Ab [200 µg/ml 0.5 ml Goat Anti-Mouse 
IgG-FITC human absorbed, fluorescein conjugated 
antibody, diluted in 0.01 M PBS in 1% (w/v) BSA and 
0.01% (w/v) sodium azide buffer solution in a ratio 1:200] 
and then the cells were permanently fixed onto their 
coverslips. The coverslips were then stained with 50 µl 
of 1 µg/ml 40-6-Diamidino-2-phenylindole (DAPI) and 
inverted onto glass microscope slides and sealed with 
nail varnish. The slides were examined using the filter 
fluorescent settings of a Carl Zeiss Axio Z1 Observer 
immuno fluorescent microscope. The 358Ex / 461Em 
filter was used to detect blue DAPI counter stained nuclei 
in cultured cells, while the 495Ex / 519Em filter was used 
to detect any green FITC stained ICAM-1 membrane 
proteins and the 589Ex / 610Em filter was used to detect 
any Cy5 red auto fluorescent signal that was produced 
from the ZnPcS4.
Cell culture and preparation of cell culture 
plates
Commercially purchased Human malignant 
melanoma cell line A375 (MM) were obtained from 
the European Collection of Authenticated Cell Cultures 
(ECACC no: 88113005) and cultured in a 175 cm2 cell 
culture flask, which contained Dulbecco's Modified 
Eagle's medium (DMEM) basal medium supplemented 
with 15% (v/v) Foetal Bovine Serum (FBS), 0.1% (v/v) 
Amphotericin-β and 0.1% (v/v) Penicillin-Streptomycin. 
The cultured cells were incubated at 37 °C, with 5% CO2 
tension and 85% humidity.
Once confluent monolayers of cultured cells were 
obtained, they were detached using Tryple ™Select. 
The cellular suspensions were then pelleted out and re-
suspended in complete cell growth medium. These cellular 
suspensions were then sub-cultured into 3.4 cm diameter 
cell culture plates at a seeding ratio of 2.5 × 105 cells/ml, 
which contained 3 ml of complete cell growth medium. 
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The culture plates were then incubated for 4 hours to allow 
for cellular attachment.
This particular cell line was purchased from ECACC 
in March 2018 and was passaged within these laboratory 
experiments for fewer than 6 months after receipt and 
so re-authentication was not required. However, the 
ECACC cell bank notes that they utilize human cell lines 
Short tandem repeat (STR) loci human cell line profiling 
methods of characterization to ensure cell line authenticity.
PDT laser parameters, PS drug addition to 
culture plates and laser irradiation
After 4 hours incubation, culture plates were divided 
into various control and experimental groups, for ZnPcS4 
PDT PS dose response or final PDT PS drug conjugate 
assays. Then the cell culture media was freshly replaced. 
The groups which required PS or final PS drug conjugate, 
had the required concentration added to their culture 
media and were incubated for an additional 20 hours. Then 
the groups which required laser treatment (wavelength: 
673 nm and fluency:10 J/cm2) were irradiated for 
approximately 16 minutes and 8 seconds in 1 ml 0.001 
M PBS using a Roithner 1000 mA 673 nm high power 
semiconductor diode laser (Arroyo 4210). The culture 
media of all plates was then freshly replaced, and plates 
were incubated for an additional 24 hours.
ZnPcS4 PS PDT dose response assays
To determine the IC50 of PS PDT treatment alone 
a concentration range between 0.25 – 10 µM of ZnPcS4 
was administered to various control and experimental 
culture plate groups, as discussed above. Post laser 
irradiation (for some groups) and after an additional 24 
hours of incubation, following detachment and cellular 
suspension these groups were subjected to Trypan blue 
and cytotoxicity analysis. Note: the IC50 of ZnPcS4 was 
found to be 2.5 µM.
ZnPcS4 – AuNP-PEG5000-SH-NH2 – Anti-MIA Ab 
final PS drug conjugate PDT response assays
Thus, to determine if the final PS drug conjugate 
enhanced PDT treatment in comparison to PS PDT 
treatment alone, 2.5 µM of the final PS drug conjugate 
and/or laser light irradiation was administered to various 
control and experimental culture plate groups, as discussed 
above. Post laser irradiation (for some groups) and after an 
additional 24 hours of incubation, following detachment 
and cellular suspension these groups were subjected to 
various biochemical assays.
Biochemical assays
Morphology
Post-PDT treatment, the effect on cellular 
morphology was viewed by light microscopy and observed 
at 400× magnification using an inverted microscope 
(Olympus CKX41) that had a digital camera (Olympus 
C5060-ADUS) attached to it.
The trypan blue exclusion test
10 ul of 0.4% (w/v) Trypan Blue stain was mixed 
with 10 µl of cellular suspensions and loaded onto a 
disposable Countess® cell counting chamber slide. The 
number of viable cells per ml was quantified using an 
Invitrogen Countess® II FL Automated Cell Counter.
LDH cellular cytotoxicity and membrane integrity assay
The CytoTox96® Non-Radioactive Cytotoxicity 
Assay (Promega, G1780), measures the amount of 
lactate dehydrogenase (LDH) that is released into culture 
medium upon cell lysis and so can be used to determine 
cellular cytotoxicity. Thus, following manufacturer’s 
instructions, 50 µl of complete cell culture media from 
each experimental and control culture plate was removed 
and added to 50 µl of LDH Reconstituted Substrate Mix 
in a flat 96 well clear bottom plate. LDH absorbance was 
recorded at 490 nm using a spectrophotometer (Perkin 
Elmer, Victor3, 1420 Multilabel Counter) and so used to 
calculate cellular lysis and cytotoxicity.
Flow cytometry Annexin V-FITC/PI cell death pathway 
detection assay
Following manufacturer’s instructions, the Annexin 
V-FITC/PI cell death detection kit (BD Scientific: 
BD/556570), was used to detect early or late apoptotic, 
as well as necrotic phases of cells death in various control 
and experimental groups, using the BD Accuri™ C6 flow 
cytometer.
Statistical analysis
Graphs represent the mean and the standard 
deviation of biochemical assays done in duplicate for six 
independent experiments. The Students t-test and one-
way analysis of variances (ANOVA), was used for normal 
distributed data, whereas the Mann-Whitney test was used 
for non-normal distributed data. These tests were used to 
determine the significance difference between control and 
experimental groups where values in the 95% confidence 
interval (P < 0.05*, P < 0.01** or P < 0.001***) were 
accepted as statistically different.
Abbreviations
MM: Metastatic melanoma; PDT: photodynamic 
therapy; PS: photosensitizer; nm: nanometre; ROS: 
reactive oxygen species; ZnPcS /ZnPcSmix: zinc sulpho 
phthalocyanine; AuNP: gold nanoparticle; MIA: 
Melanoma Inhibitory Activity; Ab: Antibody; Anti-
MIA: Anti-Melanoma Inhibitory Activity; ZnPcS4: 
Zinc phthalocyanine tetra-sulphonic acid; AuNP-
PEG5000-SH-NH2: Amine functionalized pegylated gold 
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nanoparticle; UV: Ultra Violet; µM: Micromolar; PEG: 
Polyethylene glycol; C: Carbon; S: Sulphur; H: Hydrogen; 
N: Nitrogen; NH2: Anime; ml: millilitre; µg: Microgram; O: 
Oxygen; n’: terminus Amino terminus; c’: terminus 
Carboxyl terminus; FT-IR: Fourier Transform Infrared; Au: 
Gold; DLS: Dynamic Light Scattering; ZP: Zeta 
Potential; PDI: Polydispersity Index; mV: millivolt; IC50: 
Inhibitory Concentration of 50%; J/cm2: Joules per 
cm2; LDH: Lactate Dehydrogenase; FTIC: Fluorescein 
isothiocyanate; PI: Propidium iodide; M: Molar; PBS: 
Phosphate Buffered Saline; rpm: rotation per minute; mg: 
milligrams; EDC: 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide; NHS: N-Hydroxysuccinimide; µl: 
Microliter; °C: Degree Celsius; mW: milliwatt; He-Ne: 
Helium-neon; ICAM-1: Intercellular adhesion molecule-
1; BSA: Bovine serum albumin; DAPI: 4ʼ,6-diamidino-
2-phenylindole; ECACC: European Collection of 
Authenticated Cell Cultures; DMEM: Dulbeccoʼs Modified 
Eagleʼs medium; FBS: Foetal Bovine Serum; CO2: Carbon 
dioxide; mA: milliampere; BD: Becton Dickinson; 
ANOVA: Analysis of variances.
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